Introduction: Despite significant advances in diabetes care over the last three decades, the majority of people living with T1D are not meeting established metabolic goals. Automated insulin delivery can help achieve these metabolic goals (HbA1c and TIR). Areas covered: This review examines the new features and available data regarding safety and efficacy of the MiniMed™ 780 G, a second-generation advanced hybrid closed-loop system. Reported outcomes include time in, above and below range, HbA1c, diabetic ketoacidosis and severe hypoglycemia. Expert opinion: The initial pivotal trials of the MiniMed™ 780 G have demonstrated promising clinical and safety outcomes. Real-world data and longer-term studies are still needed. The success of AID devices moving forward hinges on their ease of use and ability to reduce and relieve the burden of living with T1D.
Bibliographical noteFunding Information:
One peer reviewer has received research funding from Medtronic Diabetes. One peer reviewer’s institute has received research support from Abbott Diabetes, Eli Lilly, Insulet and Medtronic Diabetes. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
- Automated insulin delivery (aid)
- continuous glucose monitoring (cgm)
- hybrid closed loop (hcl)
- minimed™ 780g
- time in range (tir)
- type 1 diabetes (t1d)
PubMed: MeSH publication types
- Journal Article